A ribonuclease A variant with low catalytic activity but high cytotoxicity
- PMID: 10744660
- DOI: 10.1074/jbc.275.14.9893
A ribonuclease A variant with low catalytic activity but high cytotoxicity
Abstract
Onconase, a homolog of ribonuclease A (RNase A) with low ribonucleolytic activity, is cytotoxic and has efficacy as a cancer chemotherapeutic. Here variants of RNase A were used to probe the interplay between ribonucleolytic activity and evasion of the cytosolic ribonuclease inhibitor protein (RI) in the cytotoxicity of ribonucleases. K41R/G88R RNase A is a less active catalyst than G88R RNase A but, surprisingly, is more cytotoxic. Like Onconase, the K41R/G88R variant has a low affinity for RI, which apparently compensates for its low ribonucleolytic activity. In contrast, K41A/G88R RNase A, which has the same affinity for RI as does the K41R/G88R variant, is not cytotoxic. The nontoxic K41A/G88R variant is a much less active catalyst than is the toxic K41R/G88R variant. These data indicate that maintaining sufficient ribonucleolytic activity in the presence of RI is a requirement for a homolog or variant of RNase A to be cytotoxic. This principle can guide the design of new chemotherapeutics based on homologs and variants of RNase A.
Similar articles
-
Conformational stability is a determinant of ribonuclease A cytotoxicity.J Biol Chem. 2000 Jun 9;275(23):17463-7. doi: 10.1074/jbc.M001132200. J Biol Chem. 2000. PMID: 10747991
-
Compensating effects on the cytotoxicity of ribonuclease A variants.Arch Biochem Biophys. 2003 Jul 15;415(2):172-7. doi: 10.1016/s0003-9861(03)00214-5. Arch Biochem Biophys. 2003. PMID: 12831839
-
KFERQ sequence in ribonuclease A-mediated cytotoxicity.J Biol Chem. 2002 Mar 29;277(13):11576-81. doi: 10.1074/jbc.M112227200. Epub 2002 Jan 18. J Biol Chem. 2002. PMID: 11801605
-
Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.Curr Pharm Biotechnol. 2008 Jun;9(3):185-9. doi: 10.2174/138920108784567344. Curr Pharm Biotechnol. 2008. PMID: 18673284 Free PMC article. Review.
-
Ribonucleases and their antitumor activity.Comp Biochem Physiol C Toxicol Pharmacol. 2001 Jul;129(3):175-91. doi: 10.1016/s1532-0456(01)90202-9. Comp Biochem Physiol C Toxicol Pharmacol. 2001. PMID: 11461835 Review.
Cited by
-
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.Bioconjug Chem. 2010 Sep 15;21(9):1691-702. doi: 10.1021/bc100292x. Bioconjug Chem. 2010. PMID: 20704261 Free PMC article.
-
Cancer chemotherapy--ribonucleases to the rescue.Chem Biol. 2001 May;8(5):405-13. doi: 10.1016/s1074-5521(01)00030-8. Chem Biol. 2001. PMID: 11358688 Free PMC article. Review.
-
Ribonuclease inhibitor: structure and function.Prog Nucleic Acid Res Mol Biol. 2005;80:349-74. doi: 10.1016/S0079-6603(05)80009-1. Prog Nucleic Acid Res Mol Biol. 2005. PMID: 16164979 Free PMC article. Review. No abstract available.
-
Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity.Cancer Biol Ther. 2011 Aug 1;12(3):208-14. doi: 10.4161/cbt.12.3.15959. Epub 2011 Aug 1. Cancer Biol Ther. 2011. PMID: 21633186 Free PMC article.
-
A continuous fluorometric assay for the assessment of MazF ribonuclease activity.Anal Biochem. 2007 Dec 15;371(2):173-83. doi: 10.1016/j.ab.2007.07.017. Epub 2007 Jul 26. Anal Biochem. 2007. PMID: 17706586 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
